Capsugel Launches New Oral Formulation Business Unit

Capsugel announce new dosage form business unit

Capsugel says it will focus on lipid-based formulations as it launches a new Dosage Form Solutions Business Unit.

The new unit, based at the company’s headquarters in Morristown, New Jersey, will integrate formulation R&D with proprietary technology and commercial manufacturing as Capsugel aims to develop innovative products to address customer demand.

Amit Patel, who will serve as President of the Unit, said in a press release that “continuing to innovate and develop cutting-edge healthcare products is essential to maximizing the potential of the industry.”

Lipid-based Formulations

Patel also said that the new unit would focus on improvements in solid oral dosage products, including bioavailability enhancement and optimal dosing for potent APIs, and especially lipid-based formulations.

Lipid-based drug delivery systems (LBDDs) are an increasingly more important drug delivery technique as drugs become more complex and less soluble in water. LBDDs are a versatile way of enabling a higher dose to be encapsulated and more API to be absorbed.

Last June, Capsugel entered into a partnership with Quotient in order to boost its LBDDs know-how and two months later launched a non-profit consortium in order to establish a lipid formulation classification system.

Oral Formulation Driven by Bioavailability

Recently there has been a flow of collaborations and investments in the oral dose formulation sector as companies vie to lead the way in bioavailability.

This week in-Pharmatechnologist.com reported that Dow, Cambrex and Bend Research have formed a trifecta to tackle the issue, and Hovione and Solvias also teamed up late last year. Patheon, Catalent and Polypid have also heavily invested in oral dose formulation platforms. 

On the 20th March the Bioavailability Challenge will be addressed in a special online event, organized by in-Pharmatechnologist.com. For more information on speakers and how to gain access to the event, please click here.

Related News

BASF says Bend Accord Targets Different Chemistries than Dow deal

BASF says Bend Accord Targets Different Chemistries than Dow deal

Qualicaps expand oral dose manufacture: competition heats up

Oral Dose Competition Intensifies as Qualicaps Expands Manufacturing

Capsugel Buys Encap Drug Delivery

Capsugel Buys Encap as Part of Dosage Form Solution Strategy

New DFS Unit Built on Technology, R&D and Manufacturing, says Capsugel

New DFS Unit Built on Technology, R&D and Manufacturing, says Capsugel

Capsugel: Micro-Dosing Tech Can Cut Drug Development by 6 Months

Capsugel: Micro-Dosing Tech Can Cut Drug Development by 6 Months

Capsugel Launches Lipidex Encapsulating Platform from New DFS Unit

Capsugel Launches Lipidex Encapsulating Platform from New Dosage Form Unit

Collaboration could transform oral solid dose processing

Pfizer teams with GEA and G-CON to 'transform' oral solid dose industry

Bend expands SDD facility with $20m help from new owner Capsugel

Bend expands SDD services with $20m Capsugel capital injection

Capsugel: 'More than a capsule maker,' as it wins manufacturing contract

'No longer simply a capsule provider' - Capsugel wins oral peptide contract

Capsugel acquires lipid drug delivery tech based on Ionic liquid - a salt which is composed out of weakly coordinated anions and cations - from Monash University

Capsugel buys ionic liquid tech IP to enhance lipid-based drug solubility

Capsugel acquired Oregon-based bioavailability enhancement firm Bend Research in 2013

Capsugel completes $25m SDD expansion at Bend site

Pfizer to sell Capsugel for $2.4 billion

Dow collaborate with Cambrex on Bioavailability deal

Dow Signs Up Cambrex for Bioavailability Partnership

Bioavailability pushes Patheon's Solupath

Bioavailability drives Patheon and Catalent investments

Solvias buys QC capabilities

Solvias buys Confarma for EU pharma quality control capacity

Related Products

See more related products